Chonluten is a short synthetic tripeptide (Glu-Asp-Gly) developed within the Khavinson “peptide bioregulator” program at the St. Petersburg Institute of Bioregulation and Gerontology, where it is described as a bronchial peptide.1 Published English-language data are limited. The most concrete peer-reviewed finding is an in vitro study in which the Chonluten tripeptide reduced tumour necrosis factor (TNF) production by lipopolysaccharide-stimulated monocytes.2 Broader respiratory claims come largely from review articles and uncontrolled Russian clinical reports rather than randomized trials.1 Much of the detailed mechanistic and dosing information circulated by vendors is not traceable to primary studies and should be treated with caution. Chonluten is offered for laboratory research use only and is not an approved drug.
Sequence & identity
Structure and identifiers verified against PubChem CID 194641 (InChIKey DSPQRJXOIXHOHK-WDSKDSINSA-N).3
Mechanisms studied
Chonluten belongs to the Khavinson class of short peptides hypothesized to act as tissue-specific regulators of gene expression, with proposed entry into cells and binding to DNA or chromatin to modulate transcription.1 This general mechanism is a working hypothesis from the originating group rather than an established pathway for Chonluten specifically. The one directly measured activity in a peer-reviewed model is suppression of TNF release from activated monocytes in vitro, consistent with an anti-inflammatory signal in immune cells.2 Specific gene targets attributed to Chonluten in non-primary sources could not be verified and are not stated here.
Dosing in the research literature
The figures below summarise regimens as reported in published research — they are not recommendations or directions for use.
| Source / model | Regimen reported | Notes |
|---|---|---|
| Khavinson et al., 2020 (review describing reported practice) | Oral administration of the EDG tripeptide (Chonluten) as reported for bronchopulmonary pathology (chronic obstructive pulmonary disease, chronic bronchitis with an asthmatic component) | Reported as a bronchoprotector said to reduce apoptosis; the review does not specify a verified milligram dose, frequency, or course length, and these reports are not from randomized controlled trials.1 |
| Avolio et al., 2022 (in vitro) | Cell-culture exposure of THP-1 monocytes/macrophages to the Chonluten tripeptide | A laboratory concentration study, not a dosing protocol for any organism.2 |
Effects observed in research
In a controlled in vitro system, Chonluten reduced TNF production by monocytes stimulated with bacterial lipopolysaccharide, indicating an anti-inflammatory effect on these immune cells.2 Review literature from the originating group reports use of the EDG tripeptide for bronchopulmonary conditions and frames it as a bronchoprotective peptide, but these statements rest on uncontrolled clinical experience rather than blinded trials.1 No human efficacy outcome for Chonluten has been demonstrated in a randomized controlled trial in the available English literature.
Strength of evidence
Evidence grade C. The strongest published support is a single peer-reviewed in vitro study on immune-cell TNF release;2 remaining respiratory claims derive from review articles and uncontrolled reports.1 No randomized controlled clinical trials of Chonluten were identified. Chemical identity is well characterized,3 but pharmacokinetic data (including a measured half-life) for this specific tripeptide are not established in the public literature.
Reconstitution & storage
Reconstitute with bacteriostatic water for laboratory handling. Store lyophilised material frozen and reconstituted material refrigerated. Use Peptigo’s reconstitution calculator and storage cheat sheet for working figures.
References
- Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020;25(19):4389. doi:10.3390/molecules25194389. PMID 32987757.
- Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, Mironova E, Pulcini R, Robuffo I, Bologna G, Simeone P, Lanuti P, Guarnieri S, Trofimova S, Procopio AD, Toniato E. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. Int J Mol Sci. 2022;23(7):3607. doi:10.3390/ijms23073607. PMID 35408963.
- PubChem Compound Summary for CID 194641, Glu-Asp-Gly. National Library of Medicine (US), National Center for Biotechnology Information. InChIKey DSPQRJXOIXHOHK-WDSKDSINSA-N; CAS 75007-24-8.